Literature DB >> 34010066

LncRNA GAS5 inhibits miR-579-3p to activate SIRT1/PGC-1α/Nrf2 signaling pathway to reduce cell pyroptosis in sepsis-associated renal injury.

Hua Ling1, Qiong Li1, Ze-Peng Duan1, Yu-Jing Wang1, Bing-Qin Hu1, Xin-Gui Dai1.   

Abstract

Sepsis is a life-threatening condition that can lead to several organ failures including kidney. In this study, we investigated the roles of GAS5 and miR-579-3p in regulating cell pyroptosis in the sepsis-induced renal injury model. Lipopolysaccharide (LPS) treatment or cecal ligation and puncture (CLP) surgery was used to create the in vitro and in vivo sepsis-induced renal injury model. The interactions between GAS5 and miR-579-3p, miR-579-3p and SIRT1 were determined by bioinformatic prediction, luciferase reporter assay and RIP assay. In vitro cell pyroptosis was examined by flow cytometry marked with active caspase-1 and PI. The protein levels of IL-1β and IL-18 induced by cell pyroptosis were quantified using ELISA assay. In vivo renal injuries were evaluated with HE and TUNEL stainings, bacterial load in serum and creatinine and blood urea nitrogen content analyses. Expression levels of GAS5, miR-579-3p, pyroptosis and SIRT1/PGC-1a/Nrf2 pathway-related molecules were evaluated by qRT-PCR or western blot. GAS5 and SIRT1 were downregulated while miR-579-3p was upregulated in in vitro and in vivo sepsis-induced renal injury models. GAS5 negatively and directly regulated miR-579-3p to reduce cell pyroptosis via activation of SIRT1/PGC-1a/Nrf2 pathway. In addition, miR-579-3p suppressed PGC-1a/Nrf2 pathway to induce cell pyroptosis by directly targeting SIRT1. What's more, overexpression of GAS5, or knockdown of miR-579-3p, enhanced SIRT1 expression that led to the improved survival rate, reduced the weight loss, and relieved renal injuries in septic mice. Overexpression of GAS5 demonstrated protective effects against sepsis-induced renal injury via downregulating miR-579-3p and activating SIRT1/PGC-1α/Nrf2 pathway to inhibit cell pyroptosis.

Entities:  

Keywords:  Cell pyroptosis; GAS5; MiR-579-3p; PGC-1/Nrf2 pathway; Sepsis-associated renal injury

Year:  2021        PMID: 34010066     DOI: 10.1152/ajpcell.00394.2020

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  7 in total

1.  Long Non-coding RNA GAS5/miR-520-3p/SOCS3 Axis Regulates Inflammatory Response in Lipopolysaccharide-Induced Macrophages.

Authors:  Jinlong Du; Huiping Jiang; Bing Wang
Journal:  Biochem Genet       Date:  2022-01-31       Impact factor: 2.220

Review 2.  Non-Coding RNAs in Sepsis-Associated Acute Kidney Injury.

Authors:  Yanna Chen; Huan Jing; Simin Tang; Pei Liu; Ye Cheng; Youling Fan; Hongtao Chen; Jun Zhou
Journal:  Front Physiol       Date:  2022-04-08       Impact factor: 4.755

Review 3.  Molecular mechanisms and functions of pyroptosis in sepsis and sepsis-associated organ dysfunction.

Authors:  Ri Wen; Yong-Ping Liu; Xiao-Xu Tong; Tie-Ning Zhang; Ni Yang
Journal:  Front Cell Infect Microbiol       Date:  2022-07-29       Impact factor: 6.073

4.  lncRNA GAS5 Induces Cell Apoptosis in Acute Myeloid Leukemia by Targeting Nrf2.

Authors:  Xiaohua Qin; Yanling Jiang; Xiaojun Zhang; Dan Li
Journal:  Dis Markers       Date:  2022-08-24       Impact factor: 3.464

5.  miR-486-5p Serves as a Diagnostic Biomarker for Sepsis and Its Predictive Value for Clinical Outcomes.

Authors:  Baobin Sun; Shubin Guo
Journal:  J Inflamm Res       Date:  2021-07-30

6.  LncRNA GAS5 Interacts with MicroRNA-10b to Inhibit Cell Proliferation and Migration and Induces Apoptosis in Colorectal Cancer.

Authors:  Rui-Qi Yang; Zhe-Zhu Jin; San-Ya Jiang; Yong-Jun Jin
Journal:  Comput Math Methods Med       Date:  2022-01-22       Impact factor: 2.238

7.  LncRNA GAS5 relates to Th17 cells and serves as a potential biomarker for sepsis inflammation, organ dysfunctions and mortality risk.

Authors:  Weizhen Zhang; Bingqing Chen; Wei Chen
Journal:  J Clin Lab Anal       Date:  2022-03-24       Impact factor: 3.124

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.